Collectively, in breast cancer accumulating data implies PRL/PRLR as a clinically relevant potent differentiation pathway limiting the tumorigenic phenotype and thus may serve as a potential pro-differentiation therapeutic candidate. This evidence concerns the gene PRLR and breast cancer.